Tempus AI, Inc. (TEM) NASDAQ

50.93

-1.7513(-3.32%)

Updated at April 28 10:36AM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Eric Lefkofsky	Co-Founder, Chief Executive Officer, President & Chairman	805,040	1970
James Rogers	Chief Financial Officer	543,767	1986
Andrew Polovin	Executive VP, General Counsel & Secretary	594,187	1974
Ryan Fukushima	Chief Operating Officer	699,304	1985
Kate A. Sasser	Chief Scientific Officer	0	1977
Erik Phelps	Executive Vice President, Assistant Secretary and Chief Administrative & Legal Officer	0	1972
Ryan Bartolucci	Chief Accounting Officer	0	1983
Shane Colley	Chief Technology Officer	0	N/A
Elizabeth Krutoholow	Vice President of Investor Relations & Competitive Intelligence	0	N/A
Patty Spiller	Chief Marketing Officer	0	N/A

Name

Title

Pay

Year Born

Eric Lefkofsky

Co-Founder, Chief Executive Officer, President & Chairman

805,040

1970

James Rogers

Chief Financial Officer

543,767

1986

Andrew Polovin

Executive VP, General Counsel & Secretary

594,187

1974

Ryan Fukushima

Chief Operating Officer

699,304

1985

Kate A. Sasser

Chief Scientific Officer

1977

Erik Phelps

Executive Vice President, Assistant Secretary and Chief Administrative & Legal Officer

1972

Ryan Bartolucci

Chief Accounting Officer

1983

Shane Colley

Chief Technology Officer

N/A

Elizabeth Krutoholow

Vice President of Investor Relations & Competitive Intelligence

N/A

Patty Spiller

Chief Marketing Officer

N/A

Description

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.